Novartis AG $NVS Shares Bought by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC boosted its position in shares of Novartis AG (NYSE:NVS) by 5.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 300,078 shares of the company’s stock after acquiring an additional 14,273 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Novartis were worth $41,372,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the company. Manchester Capital Management LLC increased its position in Novartis by 327.3% during the fourth quarter. Manchester Capital Management LLC now owns 1,910 shares of the company’s stock worth $263,000 after buying an additional 1,463 shares during the period. Hilton Head Capital Partners LLC acquired a new position in Novartis during the fourth quarter worth approximately $363,000. Fiera Capital Corp increased its position in Novartis by 32.4% during the fourth quarter. Fiera Capital Corp now owns 124,367 shares of the company’s stock worth $17,146,000 after buying an additional 30,433 shares during the period. JPMorgan Chase & Co. increased its position in Novartis by 10.3% during the fourth quarter. JPMorgan Chase & Co. now owns 592,652 shares of the company’s stock worth $81,709,000 after buying an additional 55,109 shares during the period. Finally, IMA Advisory Services Inc. increased its position in Novartis by 10.9% during the fourth quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after buying an additional 70 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Trading Down 0.1%

Shares of NVS stock opened at $149.04 on Monday. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. Novartis AG has a twelve month low of $112.34 and a twelve month high of $170.46. The company has a market capitalization of $284.40 billion, a P/E ratio of 21.35, a price-to-earnings-growth ratio of 2.62 and a beta of 0.46. The business’s 50 day moving average is $149.57 and its two-hundred day moving average is $147.39.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). Novartis had a net margin of 24.87% and a return on equity of 38.82%. The business had revenue of $13.52 billion during the quarter, compared to analysts’ expectations of $13.44 billion. During the same quarter last year, the firm earned $2.28 earnings per share. The firm’s quarterly revenue was down .9% compared to the same quarter last year. Equities analysts forecast that Novartis AG will post 8.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a research report on Thursday, February 12th. Weiss Ratings downgraded Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Argus upgraded Novartis from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research note on Wednesday, March 11th. Sanford C. Bernstein upgraded Novartis to a “hold” rating in a research note on Thursday, March 19th. Finally, TD Cowen reiterated a “hold” rating on shares of Novartis in a research note on Tuesday, February 17th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Novartis has an average rating of “Hold” and a consensus price target of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.